Pharma BD Deal Intelligence

ImmunoPrecise Antibodies Ltd. / RiboPro

2025 · Co-Development · Complete

ImmunoPrecise Antibodies announced a strategic collaboration with RiboPro, an mRNA and lipid nanoparticle technology provider, to integrate RiboPro's mRNA-based antigen expression and LNP delivery expertise with ImmunoPrecise's in silico and wet-lab antibody discovery platform, including B-cell screening, single-cell analysis and deep-learning discovery workflows. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals